Cargando…

α‐galactosylceramide generates lung regulatory T cells through the activated natural killer T cells in mice

Our previous study showed that intraperitoneal injection of α‐galactosylceramide (α‐GalCer) has the ability to activate lung iNKT cells, but α‐GalCer‐activated iNKT cells do not result in airway inflammation in wild‐type (WT) mice. Many studies showed that iNKT cells had the capacity to induce Treg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Qianhui, Guo, Xuxue, Deng, Nishan, Liu, Linlin, Chen, Shuo, Wang, Ailing, Li, Ruiyun, Huang, Yi, Ding, Xuhong, Yu, Hongying, Hu, Suping, Nie, Hanxiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349240/ https://www.ncbi.nlm.nih.gov/pubmed/30421497 http://dx.doi.org/10.1111/jcmm.14008

Ejemplares similares

The role of plasma N-terminal brain natriuretic pro-peptide in diagnosing elderly patients with acute exacerbation of COPD concurrent with left heart failure
por: Guo, Xuxue, et al.
Publicado: (2018)

Natural Killer Dendritic Cells Enhance Immune Responses Elicited by α-Galactosylceramide-Stimulated Natural Killer T Cells
por: Lee, Sung Won, et al.
Publicado: (2013)

Phenotypic switch in lung interstitial macrophage polarization in an ovalbumin-induced mouse model of asthma
por: Nie, Hanxiang, et al.
Publicado: (2017)

Natural Killer T Cell Ligand α-Galactosylceramide Enhances Protective Immunity Induced by Malaria Vaccines
por: Gonzalez-Aseguinolaza, Gloria, et al.
Publicado: (2002)

Exogenous Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Reduces Pneumococcal Outgrowth and Dissemination Postinfluenza
por: Barthelemy, Adeline, et al.
Publicado: (2016)

CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

Natural Killer T Cell Ligand α‐Galactosylceramide Inhibited Lymph Node Metastasis of Highly Metastatic Melanoma Cells
por: Nakui, Minoru, et al.
Publicado: (1999)

Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

CD1d-mediated Recognition of an α-Galactosylceramide by Natural Killer T Cells Is Highly Conserved through Mammalian Evolution
por: Brossay, Laurent, et al.
Publicado: (1998)

Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide
por: Croudace, Joanne E, et al.
Publicado: (2008)

Invariant NKT Cells Act as an Adjuvant to Enhance Th2 Inflammatory Response in an OVA-Induced Mouse Model of Asthma
por: Nie, Hanxiang, et al.
Publicado: (2015)

Superior Protection against Malaria and Melanoma Metastases by a C-glycoside Analogue of the Natural Killer T Cell Ligand α-Galactosylceramide
por: Schmieg, John, et al.
Publicado: (2003)

α-galactosylceramide-stimulated invariant natural killer T-cells play a protective role in murine vulvovaginal candidiasis by Candida albicans
por: Abe, Masahiro, et al.
Publicado: (2021)

Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer
por: Wang, Ying, et al.
Publicado: (2020)

Expansion of Lung Vα14 NKT Cells by Administration of α‐Galactosylceramide‐pulsed Dendritic Cells
por: Akutsu, Yasunori, et al.
Publicado: (2002)

Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15
por: Hsu, Chien-Ya, et al.
Publicado: (2021)

Efficient synthesis of α-galactosylceramide and its C-6 modified analogs
por: Li, Huiting, et al.
Publicado: (2022)

Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Attenuates the Development of Angiotensin II-Mediated Abdominal Aortic Aneurysm in Obese ob/ob Mice
por: Saito, Akimichi, et al.
Publicado: (2021)

Tumor-infiltrating effector cells of α-galactosylceramide-induced antitumor immunity in metastatic liver tumor
por: Osada, Takuya, et al.
Publicado: (2004)

Intra-Peritoneal Hyperthermia Combining α-Galactosylceramide in the Treatment of Ovarian Cancer
por: Wu, Chao-Chih, et al.
Publicado: (2013)

Production of α-Galactosylceramide by a Prominent Member of the Human Gut Microbiota
por: Wieland Brown, Laura C., et al.
Publicado: (2013)

Evaluating α-galactosylceramide as an adjuvant for live attenuated influenza vaccines in pigs
por: Artiaga, Bianca L., et al.
Publicado: (2022)

Characterization of a Glycolipid Synthase Producing α-Galactosylceramide in Bacteroides fragilis
por: Caballé, Marc, et al.
Publicado: (2022)

The Natural Killer T (NKT) Cell Ligand α-Galactosylceramide Demonstrates Its Immunopotentiating Effect by Inducing Interleukin (IL)-12 Production by Dendritic Cells and IL-12 Receptor Expression on NKT Cells
por: Kitamura, Hidemitsu, et al.
Publicado: (1999)

Efficient Divergent Synthesis of New Immunostimulant 4″-Modified α-Galactosylceramide Analogues
por: Janssens, Jonas, et al.
Publicado: (2017)

Synthesis and Immunological Activity of Novel Oligo(ethylene glycol) Analogues of α-Galactosylceramide
por: Pawar, Mithun S., et al.
Publicado: (2022)

Activation of Natural Killer T Cells by α-Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein
por: Fujii, Shin-ichiro, et al.
Publicado: (2003)

In vitro anti-tumour activity of α-galactosylceramide-stimulated human invariant Vα24+NKT cells against melanoma
por: Kikuchi, A, et al.
Publicado: (2001)

The Molecular Basis for Recognition of CD1d/α-Galactosylceramide by a Human Non-Vα24 T Cell Receptor
por: López-Sagaseta, Jacinto, et al.
Publicado: (2012)

Structure and binding kinetics of three different human CD1d–α-galactosylceramide–specific T cell receptors
por: Gadola, Stephan D., et al.
Publicado: (2006)

α‐Galactosylceramide‐activated murine NK1.1(+) invariant‐NKT cells in the myometrium induce miscarriages in mice
por: Ichikawa, Tomoko, et al.
Publicado: (2016)

Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine
por: Gableh, Fateme, et al.
Publicado: (2016)

NKT Cell Stimulation with α-Galactosylceramide Results in a Block of Th17 Differentiation after Intranasal Immunization in Mice
por: Zygmunt, Beata M., et al.
Publicado: (2012)

Soluble and Exosome-Bound α-Galactosylceramide Mediate Preferential Proliferation of Educated NK Cells with Increased Anti-Tumor Capacity
por: Wagner, Arnika K., et al.
Publicado: (2021)

α-Galactosylceramide protects swine against influenza infection when administered as a vaccine adjuvant
por: Artiaga, Bianca L., et al.
Publicado: (2016)

Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses
por: Zhang, Lianjun, et al.
Publicado: (2017)

Alpha-galactosylceramide enhances mucosal immunity to oral whole-cell cholera vaccines
por: Davitt, Christopher J. H., et al.
Publicado: (2019)

Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer
por: Toyoda, Takahide, et al.
Publicado: (2020)

Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma
por: Escribà-Garcia, Laura, et al.
Publicado: (2017)

Clinical features in 52 patients with COVID-19 who have increased leukocyte count: a retrospective analysis
por: Zhao, Kaochang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bheqfvuco5k2g35eib637ackrr